Phospho-IRAK1 (S376) Antibody

How is IRAK1 S376 phosphorylation typically detected in experimental settings?

Detection of IRAK1 S376 phosphorylation is predominantly accomplished using phospho-specific antibodies through several techniques:

• Western blotting: The most common method, allowing for semi-quantitative assessment of phosphorylation status

• Immunohistochemistry (IHC): For detection in tissue sections with spatial context

• ELISA: For quantitative measurement of phospho-IRAK1 levels

• Immunofluorescence: For subcellular localization studies

Commercial antibodies specifically targeting this phosphorylation site are available from several vendors. For optimal results, researchers should validate antibody specificity using positive controls (e.g., IL-1β-stimulated cells with calyculin A treatment) . When designing experiments, consider using phosphatase inhibitors during sample preparation to preserve phosphorylation status, as demonstrated in studies where PP1γ treatment was used to demonstrate phosphorylation effects .

What are the functional differences between IRAK1 phosphorylation at S376 versus T209?

Research indicates significant functional distinctions between these phosphorylation sites:

• T209 phosphorylation: More consistently associated with IRAK1 activation across multiple cell types. In HCC cells, MDS cells, and breast cancer cells, T209 phosphorylation strongly correlates with IRAK1 activity and is inhibited by IRAK1/4 inhibitors .

• S376 phosphorylation: Appears less consistently across cell types. In studies examining the mechanism of IRAK1 activation, S376 phosphorylation was not detected in several liver cancer cell lines , while in other contexts such as breast cancer, both S376 and T209 phosphorylation were observed following paclitaxel treatment .

Experimental evidence from multiple studies suggests that the T209 site is more consistently linked to IRAK1 kinase activity, while S376 may have more context-dependent roles. When investigating IRAK1 activation, researchers should consider examining both phosphorylation sites to obtain a comprehensive understanding of IRAK1 regulation in their specific experimental system .

How does inhibition of IRAK1 phosphorylation at S376 versus T209 differentially affect downstream signaling pathways?

The differential effects of inhibiting phosphorylation at these sites reflect distinct roles in signaling cascades:

T209 phosphorylation inhibition consistently impairs:

• NF-κB pathway activation

• Production of inflammatory cytokines (IL-6, IL-8, CXCL1)

• Cell proliferation in multiple cancer models

S376 phosphorylation appears less consistently linked to specific outcomes, though limited evidence suggests it may contribute to:

• Interaction with Pellino proteins via their Forkhead-associated domains

• Context-specific functions in certain cancer types

In experimental designs examining these differences, researchers should:

• Use site-specific phosphorylation antibodies to monitor effects

• Employ site-directed mutagenesis (S376A and T209A) to dissect site-specific functions

• Examine multiple downstream readouts including NF-κB activation, cytokine production, and proliferation markers

• Consider temporal dynamics, as different phosphorylation events may occur in sequence

Research in MDS cells demonstrated that IRAK1 was overexpressed and activated with T209 phosphorylation, while S376 was not phosphorylated in the cell lines examined . This suggests that targeting T209 phosphorylation may be more universally effective in therapeutic approaches.

What methodological considerations are crucial when measuring IRAK1 S376 phosphorylation in tissue samples?

Successful detection of p-IRAK1 (S376) in tissue samples requires careful attention to several methodological factors:

• Tissue fixation and processing:

  • Optimal fixation with formaldehyde (recommended duration: 24 hours)

  • Antigen retrieval using citrate buffer (pH 6.0) with heat mediation is critical for unmasking the epitope

  • Blocking with 3% BSA for 30 minutes at room temperature to reduce background

• Antibody incubation parameters:

  • Primary antibody dilution: 1:25 to 1:300 range, with optimization recommended for each tissue type

  • Incubation time: 1 hour at 37°C has shown good results

  • Secondary antibody system: Biotinylated secondary antibodies provide signal amplification

• Controls and validation:

  • Positive control tissues: Testis and kidney tissues have shown consistent staining

  • Treatment controls: Compare samples with and without IL-1β stimulation

  • Peptide competition assays to confirm specificity

• Data interpretation considerations:

  • Evaluate both staining intensity and distribution pattern

  • Compare with other IRAK1 phosphorylation sites (particularly T209)

  • Correlate with downstream pathway activation markers

These parameters have been validated in published research and commercial antibody validation studies .

How can IRAK1 S376 phosphorylation be effectively measured in immunoprecipitation kinase assays?

Developing reliable immunoprecipitation (IP) kinase assays for p-IRAK1 (S376) requires:

• Optimized immunoprecipitation protocol:

  • Lysis in buffer containing 50 mM Tris-HCl (pH 7.5), 1 mM EGTA, 1 mM EDTA, 1% (v/v) Triton X-100, protease inhibitors, and phosphatase inhibitors

  • Pre-clearing lysate with protein G beads to reduce background

  • Incubation with specific anti-IRAK1 antibody (4 μg per mg of protein)

  • Careful washing steps (3-5 times) with buffers containing decreasing salt concentrations

• Kinase assay conditions:

  • Resuspend IP beads in kinase assay buffer (50 mM Tris-HCl pH 7.5, 0.1 mM EGTA, 2 mM dithiothreitol, 10 mM magnesium acetate)

  • Include 0.5 mM [γ-32P]ATP (specific radioactivity 2000 cpm/pmol)

  • Use GST-Pellino1 (0.5 μg/reaction) as substrate

  • Incubate for 30 minutes at 30°C with continuous agitation

• Phosphorylation analysis:

  • Terminate reactions with 1% SDS

  • Analyze by SDS-PAGE and autoradiography

  • Include controls with IRAK1/4 inhibitor to confirm specificity

  • Quantify phosphorylation by phosphorimager analysis

This methodology has been successfully employed to distinguish between IRAK1 and IRAK4 activities in cell extracts, enabling researchers to study these kinases independently .

What are the challenges and solutions in distinguishing allosteric activation versus phosphorylation-dependent activation of IRAK1?

Research has revealed that IRAK1 activation involves complex mechanisms beyond simple phosphorylation events:

Challenges:

• IRAK1 undergoes both phosphorylation and ubiquitylation after stimulation

• Phosphorylation may be a consequence rather than cause of activation

• Allosteric effects from IRAK4 interaction appear crucial but are difficult to measure directly

• Commercial antibodies only detect specific phosphorylation sites

Methodological solutions:

• Sequential modification analysis:

  • Immunoprecipitate IRAK1 followed by sequential deubiquitylation and dephosphorylation

  • Measure kinase activity at each step using Pellino1 as substrate

  • Studies using this approach showed that unmodified IRAK1 retained activity similar to phosphorylated/ubiquitylated species

• Mutational analysis:

  • Generate phospho-deficient mutants (e.g., T209A, S376A)

  • Assess kinase activity and downstream signaling impacts

  • Compare with wild-type IRAK1 overexpression effects

• IRAK4-interaction studies:

  • Use co-immunoprecipitation to assess IRAK1-IRAK4 interaction kinetics

  • Employ IRAK4 kinase inhibitors to distinguish between scaffold and kinase functions

  • Research demonstrates that IL-1-dependent interaction between IRAK1 and IRAK4 is sustained for at least an hour in IL-1R cells

These approaches collectively suggest that IRAK1 activation likely occurs primarily through an allosteric mechanism induced by interaction with IRAK4, rather than being dependent on phosphorylation events .

How can researchers effectively interpret contradictory data regarding IRAK1 S376 phosphorylation across different disease models?

When encountering contradictory data regarding IRAK1 S376 phosphorylation, researchers should systematically evaluate several factors:

• Cell/tissue type-specific variations:

  • MDS studies showed no S376 phosphorylation in cell lines exhibiting IRAK1 overactivation

  • Breast cancer cells showed both S376 and T209 phosphorylation after paclitaxel treatment

  • Liver cancer cells displayed minimal S376 phosphorylation despite strong T209 signal

• Stimulus-dependent differences:

  • IL-1β stimulation may induce different phosphorylation patterns compared to TLR ligands

  • Paclitaxel treatment in breast cancer cells induced robust phosphorylation at both sites

  • Different chemotherapeutic agents (adriamycin, cisplatin) induced minimal cytokine responses compared to paclitaxel

• Technical considerations:

  • Antibody specificity and sensitivity can vary significantly between vendors

  • Sample preparation methods (particularly phosphatase inhibitor usage)

  • Timing of analysis after stimulation

• Experimental validation approaches:

  • Direct comparison of multiple antibodies against the same samples

  • Parallel analysis of multiple phosphorylation sites

  • Functional readouts to correlate phosphorylation with biological effects

  • Mass spectrometry to identify and quantify site-specific phosphorylation

This integrative approach helps reconcile seemingly contradictory observations, revealing context-dependent roles for S376 phosphorylation across different biological systems.

How does IRAK1 S376 phosphorylation compare between hepatocellular carcinoma and normal liver tissue?

Research on IRAK1 phosphorylation in hepatocellular carcinoma (HCC) has revealed important distinctions:

• IRAK1 is overexpressed at both mRNA and protein levels in HCC tissues compared to normal liver tissues

• Phosphorylation at T209 appears to be the predominant activation mechanism in HCC cells, with studies showing that p-IRAK1 (T209) was significantly expressed in SMMU-7721 and HepG2 cells

• In contrast, p-IRAK1 (S376) was minimally expressed in these HCC cell lines

When designing studies to investigate these differences:

• Include paired tumor/normal tissue samples from the same patients

• Use immunohistochemistry to evaluate spatial distribution of phosphorylation

• Correlate with clinical parameters (tumor stage, grade, patient outcomes)

• Validate findings with functional assays (proliferation, migration, invasion)

Inhibition of IRAK1 using siRNA or IRAK1/4 inhibitor impeded cell growth, induced apoptosis, and reduced HCC xenograft tumor growth, confirming IRAK1 as a potential therapeutic target . Since T209 appears to be the predominant phosphorylation site in HCC, researchers should focus on this site as a primary biomarker when studying HCC.

What methodological approaches best reveal the role of IRAK1 S376 phosphorylation in cancer stem cell formation?

Investigating IRAK1 S376 phosphorylation in cancer stem cell (CSC) biology requires specialized methodologies:

• CSC isolation and characterization:

  • Aldefluor assay to measure aldehyde dehydrogenase (ALDH) activity as a CSC marker

  • Mammosphere formation assays to assess functional CSC properties

  • Flow cytometric analysis of CSC surface markers (CD44+/CD24-/low for breast CSCs)

• Chemotherapy-induced CSC enrichment models:

  • Treat cancer cells (e.g., SUM159, MDA231) with paclitaxel (10 nM for 4 days)

  • Remove floating dead cells and analyze remaining viable cells for CSC properties

  • Monitor both S376 and T209 phosphorylation in response to treatment

• Cytokine induction analysis:

  • Measure expression of IL1B, IL6, and IL8 after chemotherapy treatment

  • Compare effects of different chemotherapeutic agents (paclitaxel vs. adriamycin vs. cisplatin)

  • Assess impact of IRAK1 knockdown on cytokine induction

• Functional validation:

  • Combine IRAK1 inhibitors with anti-CSC agents

  • Assess impact on tumor-initiating capacity in limiting dilution assays

  • Monitor long-term tumor recurrence after treatment

Research in breast cancer cells demonstrated that paclitaxel treatment induced IRAK1 phosphorylation at both T209 and S376, accompanied by inflammatory cytokine induction and CSC enrichment . This suggests both phosphorylation sites may play roles in chemotherapy-induced CSC phenotypes.

What are the best experimental designs to evaluate IRAK1 inhibitors in targeting diseases where S376 phosphorylation is observed?

Rigorous evaluation of IRAK1 inhibitors in diseases featuring S376 phosphorylation should include:

• In vitro assessment:

  • Dose-response experiments (typically 0-20 μM range)

  • Monitor both T209 and S376 phosphorylation inhibition

  • Assess cell viability, proliferation, and apoptosis (CCK-8 assays, flow cytometry)

  • Colony formation assays for long-term effects

  • Migration/invasion assays for metastatic potential

• Cell cycle and apoptosis analysis:

  • Flow cytometry for cell cycle distribution (look for G1/S arrest)

  • Measure apoptosis markers (Annexin V/PI staining)

  • Western blotting for apoptotic proteins (cleaved caspase-3, PARP)

• In vivo models:

  • Subcutaneous xenograft models with tumor volume and weight measurements

  • Treatment with IRAK1/4 inhibitor (optimized dosage from pilot studies)

  • Immunohistochemical assessment of proliferation markers (Ki-67)

  • Monitor potential toxicity (body weight, food intake, activity)

• Combination strategies:

  • Co-treatment with established therapies (chemotherapy, targeted agents)

  • Sequential treatment regimens

  • Assessment of synergistic potential (combination index calculation)

Research in HCC demonstrated that IRAK1/4 inhibitor treatment (0-20 μM) caused dose-dependent inhibition of phosphorylated IRAK1, leading to decreased proliferation, G1/S cell cycle arrest, and increased apoptosis . Similar approaches have proven effective in MDS models .

What are the key technical challenges in achieving consistent detection of IRAK1 S376 phosphorylation in western blotting?

Consistent detection of p-IRAK1 (S376) requires attention to several technical factors:

• Sample preparation:

  • Rapid lysis in buffer containing phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate)

  • Maintenance of cold temperatures throughout processing

  • Inclusion of protease inhibitors to prevent degradation

  • Standardization of protein loading (20-50 μg total protein per lane)

• Phosphorylation preservation:

  • Addition of calyculin A (100 nM) to cell cultures prior to lysis improves phosphorylation detection

  • Avoid repeated freeze-thaw cycles of lysates

  • Consider using phosphatase inhibitor cocktails that target multiple phosphatase classes

• Antibody selection and optimization:

  • Validate antibody specificity with positive controls (IL-1β-stimulated cells)

  • Optimize primary antibody dilution (typically 1:500-1:2000)

  • Adjust incubation conditions (overnight at 4°C often yields better results)

  • Use high-sensitivity detection systems (ECL substrates)

• Signal verification approaches:

  • Include competing phosphopeptide controls

  • Compare with total IRAK1 detection

  • Use IRAK1 knockdown cells as negative controls

  • Analyze multiple phosphorylation sites simultaneously

Western blotting analysis of HeLa cells with and without IL-1β (20 ng/ml) plus calyculin A (100 nM) treatment has been demonstrated as an effective positive control system for validating p-IRAK1 (S376) antibody performance .

How can researchers effectively differentiate between IRAK1 and IRAK4 activities in complex signaling cascades?

Distinguishing between IRAK1 and IRAK4 activities requires sophisticated experimental approaches:

• Selective pharmacological inhibition:

  • Use IRAK1/4 inhibitor at varying concentrations to distinguish effects

  • IRAK4-selective inhibitors (when available)

  • JNK-IN-7 for IRAK1-selective inhibition

  • Monitor effects on downstream signaling events

• Immunoprecipitation kinase assays:

  • Immunoprecipitate IRAK1 and IRAK4 separately

  • Use Pellino1 as substrate for both kinases

  • Include inhibitor controls to confirm specificity

  • This approach revealed that IRAK4 is constitutively active while IRAK1 is activated upon stimulation

• Genetic approaches:

  • IRAK1 or IRAK4 knockout/knockdown cell models

  • Reconstitution with wild-type or kinase-dead mutants

  • IRAK1 knockout IL-1R cells have shown enhanced IL-1-dependent autophosphorylation of IRAK4

• Temporal analysis:

  • Monitor activation kinetics of both kinases after stimulation

  • IRAK4 is activated earlier in the signaling cascade

  • Sustained IRAK1-IRAK4 interaction occurs for at least an hour in IL-1R cells

Research using these approaches has revealed that IRAK4 is constitutively active and undergoes trans-autophosphorylation upon MyD88-induced dimerization, while IRAK1 is inactive in unstimulated cells and activated through interaction with IRAK4, likely via an allosteric mechanism rather than phosphorylation .

What are the optimal conditions for preserving and detecting IRAK1 S376 phosphorylation in immunohistochemistry applications?

Successful immunohistochemical detection of p-IRAK1 (S376) requires careful optimization:

• Tissue preparation and fixation:

  • Fixation with formaldehyde (recommended duration: 24 hours)

  • Paraffin embedding using standard protocols

  • Section thickness of 4-5 μm provides optimal results

  • Use positively charged slides to prevent tissue loss

• Antigen retrieval protocol:

  • Heat-mediated antigen retrieval with citrate buffer (pH 6.0)

  • Pressure cooker method (15 minutes) or microwave (3 × 5 minutes)

  • Cool slides slowly to room temperature (approximately 20 minutes)

  • This step is critical for unmasking phospho-epitopes

• Blocking and antibody incubation:

  • Block with 3% BSA for 30 minutes at room temperature

  • Primary antibody dilution: 1:25 - 1:300 (optimization required)

  • Incubation time: 1 hour at 37°C or overnight at 4°C

  • Secondary detection system: Biotinylated secondary antibody followed by streptavidin-HRP

• Signal development and counterstaining:

  • DAB (3,3'-diaminobenzidine) for chromogenic detection

  • Brief development time (3-5 minutes) with monitoring

  • Hematoxylin counterstaining (light blue)

  • Appropriate controls (negative: omit primary antibody; positive: testis or kidney tissue)

Validated protocols have demonstrated successful staining in human testis and kidney tissues, providing reliable positive controls for protocol optimization .

How can researchers design experiments to distinguish between functional consequences of different IRAK1 phosphorylation sites?

To differentiate functional roles of distinct IRAK1 phosphorylation sites:

• Site-directed mutagenesis approach:

  • Generate phospho-mimetic mutants (S376D/E, T209D/E)

  • Generate phospho-deficient mutants (S376A, T209A)

  • Create double mutants to assess combinatorial effects

  • Express in IRAK1-knockout backgrounds for clean interpretation

• Phospho-specific antibody mapping:

  • Monitor multiple phosphorylation sites simultaneously in time-course experiments

  • Correlate specific phosphorylation events with functional outcomes

  • Use specific stimuli (IL-1β, TLR ligands, chemotherapy agents)

  • Compare patterns across cell types and disease models

• Domain-specific interaction studies:

  • Assess interaction with downstream effectors (Pellino1, TRAF6)

  • Map binding domains affected by specific phosphorylation events

  • Research indicates S376 phosphorylation may affect interaction with Forkhead-associated domains of Pellino isoforms

• Functional readouts tailored to phosphorylation sites:

  • Proliferation/cell cycle (associated with T209 phosphorylation)

  • Cytokine production (IL-6, IL-8, CXCL1)

  • NF-κB activation (luciferase reporter assays)

  • Specific downstream signaling pathway activation

Research in HCC models demonstrated that inhibition of T209 phosphorylation strongly correlated with decreased proliferation and increased apoptosis , while studies in breast cancer showed both S376 and T209 phosphorylation were induced by paclitaxel treatment and associated with inflammatory cytokine production .

What methodological innovations would advance our understanding of IRAK1 S376 phosphorylation in disease progression?

Several innovative approaches could significantly enhance research in this area:

• Proximity ligation assays:

  • Visualize and quantify specific phosphorylation events in situ

  • Map spatial relationships between phosphorylated IRAK1 and interacting proteins

  • Detect rare or transient phosphorylation events in complex tissues

• Mass spectrometry-based phosphoproteomics:

  • Parallel quantification of multiple phosphorylation sites

  • Identification of novel phosphorylation events

  • Temporal mapping of phosphorylation cascades

  • Correlation of phosphorylation patterns with disease stages

• Single-cell analysis technologies:

  • Assess phosphorylation heterogeneity within tumors

  • Correlate with cell state and functional outcomes

  • CyTOF (mass cytometry) for multi-parameter single-cell analysis

  • Single-cell RNA-seq to correlate phosphorylation with transcriptional programs

• Targeted protein degradation approaches:

  • PROTAC technology targeting specific phosphorylated forms of IRAK1

  • Compare effects of degradation versus kinase inhibition

  • Potential for greater specificity than traditional inhibitors

• CRISPR-based screening platforms:

  • Identify genes that modulate specific IRAK1 phosphorylation events

  • Screen for synthetic lethal interactions with IRAK1 phosphorylation states

  • Engineer precise mutations at endogenous loci

These approaches would provide deeper mechanistic insights into context-dependent roles of S376 phosphorylation across different disease models and potential therapeutic applications.

How might targeting IRAK1 S376 phosphorylation specifically differ from general IRAK1 inhibition as a therapeutic strategy?

Site-specific targeting presents distinct advantages and challenges compared to general IRAK1 inhibition:

Potential advantages:

• Pathway selectivity:

  • S376 phosphorylation may regulate specific downstream pathways

  • Targeting this site could modulate selected functions while preserving others

  • Potentially reduced off-target effects compared to complete IRAK1 inhibition

• Context-dependent efficacy:

  • May be particularly effective in diseases where S376 phosphorylation is predominant

  • Could provide complementary approach to T209-focused strategies

  • Potential for combination with other phospho-site inhibitors

• Resistance mechanism bypass:

  • Alternative strategy for contexts where general IRAK1 inhibitors develop resistance

  • Different mechanism of action compared to ATP-competitive inhibitors

Research approaches to evaluate this strategy:

• Structure-guided drug design:

  • Develop compounds that specifically recognize S376-phosphorylated conformations

  • Allosteric inhibitors that prevent S376 phosphorylation

  • Peptide-based inhibitors mimicking regions around S376

• Comparative efficacy studies:

  • Direct comparison with general IRAK1 inhibitors across disease models

  • Evaluation in resistant cell lines

  • Assessment of toxicity profiles

• Biomarker development:

  • Identification of contexts where S376-specific targeting would be most effective

  • Development of companion diagnostics for patient selection

  • Correlation with response to existing therapies